Phase III data in The Lancet show significant benefit of Novartis drug Afinitor® in patients with non-cancerous tumors associated with TSC
Data published today...
11 January 2013 | By Novartis
Data published today...
List view / Grid view
Data published today...
11 January 2013 | By Novartis
Data published today...
The FDA has approved Afinitor® tablets...
26 April 2012 | By Novartis
The FDA has approved Afinitor® tablets...
A Phase III study of Afinitor® (everolimus) tablets* met its…
23 September 2011 | By Novartis
A Phase III study of Afinitor® (everolimus) tablets* met its primary endpoint of best overall angiomyolipoma response rate...